Processa Pharmaceuticals Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Processa Pharmaceuticals Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Enrollment in marketing by a regulatory agency (Approved).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| PCS499 | n/a | n/a | Phase 2/3 | Public pipeline row |
| PCS12852 | gastroparesis and GI motility | n/a | Phase 2 | Public pipeline row |
| PCS6422 | Advanced, Refractory GI Tract Tumors | n/a | n/a | Public pipeline row |
| Enrollment | marketing by a regulatory agency | n/a | Approved | Public pipeline row |
| Filter By | Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study | n/a | Phase 2 | Public pipeline row |
| RX-3117 | Metastatic Pancreatic Cancer | n/a | Phase 1 | Phase 2 | Public pipeline row |
Estimated cash runway: Runway < 6 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT02030067 | Phase 1 | Phase 2 | COMPLETED | 127 | 2019-07 |
| NCT03189914 | Phase 1 | Phase 2 | COMPLETED | 46 | 2019-10-01 |
| NCT05270460 | Phase 2 | COMPLETED | 25 | 2022-09-29 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.